新股消息 | 據悉再鼎醫藥、中通快遞分別將港股IPO價格定在562港元、218港元
uSMART友信智投9月22日消息,兩隻二次上市中概股將於今日正午結束招股。
據彭博報道,再鼎醫藥-SB據稱引導將香港IPO價格定在每股562港元,其美股昨日收盤價爲73.3美元(568港元),即港股定價約折讓1.1%。
中通快遞-SW據稱將引導香港IPO價格定在每股218港元,其美股昨日收盤價爲28.68美元(222.3港元),即港股定價約折讓1.9%。
再鼎醫藥和中通快遞將分別於25日、28日公佈中籤結果,在此期間美股的走勢將影響暗盤及首日表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.